このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

活動性乾癬性関節炎の軸性疾患を有するバイオナイーブ参加者に皮下投与されたグセルクマブの研究 (STAR)

2026年11月2日 更新者:Janssen Research & Development, LLC

アクティブな乾癬性関節炎の軸性疾患を有するバイオナイーブな参加者に皮下投与されたグセルクマブの有効性と安全性を評価する第4相、多施設、無作為化、二重盲検、プラセボ対照試験

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

調査の概要

状態

積極的、募集していない

詳細な説明

PsA is a chronic inflammatory musculoskeletal disease that has 6 disease domains, and axial disease represents one of the domains. Guselkumab is a fully human immunoglobulin (Ig) G1 lambda monoclonal antibody (mAb) that by binding to the p19 protein subunit of interleukin (IL)-23, blocks the binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23-mediated intracellular signaling, activation, and cytokine production. This study will consist of a screening phase (up to 6 weeks), a treatment phase (up to 48 weeks, including a placebo-controlled period from Week 0 to Week 24 and an active-controlled treatment phase from Week 24 to Week 48), and a safety follow-up phase (up to Week 60). The efficacy assessments will include assessment such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and the safety assessments will include evaluations of physical examinations, vital signs, electrocardiograms, clinical laboratory tests, and adverse events. The overall duration of the study will be up to 14 months.

研究の種類

介入

入学 (実際)

411

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Arizona
      • Avondale、Arizona、アメリカ、85392
        • Arizona Arthritis and Rheumatology Research PLLC 1
      • Chandler、Arizona、アメリカ、85225
        • Arizona Arthritis & Rheumatology Research, PLLC
      • Mesa、Arizona、アメリカ、85210
        • Arizona Arthritis and Rheumatology Research PLLC
      • Phoenix、Arizona、アメリカ、85032
        • Arizona Arthritis Research, PLC.
      • Sun City、Arizona、アメリカ、85351
        • Arizona Arthritis and Rheumatology Associates
      • Tucson、Arizona、アメリカ、85723
        • Southern Arizona VA Healthcare System
    • Arkansas
      • Searcy、Arkansas、アメリカ、72143
        • Unity Health-White County Medical Center
    • California
      • Fontana、California、アメリカ、92335
        • Kaiser Permanent Medical Center
      • Huntington Beach、California、アメリカ、92648
        • Newport Huntington Medical Group
      • La Jolla、California、アメリカ、92093
        • University Of California San Diego
      • San Diego、California、アメリカ、92128
        • Rheumatology Center of San Diego
    • Connecticut
      • Danbury、Connecticut、アメリカ、06810
        • Clinical Research Center of Connecticut
    • Florida
      • Bay Pines、Florida、アメリカ、33744
        • Bay Pines VA Healthcare System
      • Plantation、Florida、アメリカ、33324
        • Integral Rheumatology And Immunology Specialists
      • Zephyrhills、Florida、アメリカ、33542
        • Florida Medical Clinic, P.A.
    • Illinois
      • Chicago、Illinois、アメリカ、60640
        • Great Lakes Clinical Trials
      • Rockford、Illinois、アメリカ、61114
        • OrthoIllinois
      • Willowbrook、Illinois、アメリカ、60527
        • Willow Rheumatology and Wellness
    • Maryland
      • Baltimore、Maryland、アメリカ、21224
        • Johns Hopkins Bayview Medical
      • Hagerstown、Maryland、アメリカ、21740
        • Klein And Associates M D P A
    • Michigan
      • Saint Clair Shores、Michigan、アメリカ、48081
        • Clinical Research Institute of Michigan, LLC
    • Minnesota
      • Eagan、Minnesota、アメリカ、55121
        • St. Paul Rheumatology P A
    • Missouri
      • Kansas City、Missouri、アメリカ、64111
        • Kansas City Physician Partners
      • Springfield、Missouri、アメリカ、65807
        • Clinvest
    • Ohio
      • Vandalia、Ohio、アメリカ、45377
        • STAT Research, Inc.
    • Oregon
      • Portland、Oregon、アメリカ、97239
        • OHSU Rheumatology Clinic, Marquam Hill
    • Texas
      • Amarillo、Texas、アメリカ、79124
        • Amarillo Center for Clinical Research
      • Austin、Texas、アメリカ、78731
        • Austin Regional Clinic
      • Colleyville、Texas、アメリカ、76034
        • Precision Comprehensive Clinical Research Solutions
      • Corpus Christi、Texas、アメリカ、78404
        • Adriana Pop Moody MD Clinic PA
      • Fort Worth、Texas、アメリカ、76109
        • AARA Clinical Research Lone Star Arthritis and Rheumatology 1
      • Houston、Texas、アメリカ、77030
        • UT Physicians Center for Autoimmunity
      • Irving、Texas、アメリカ、75039
        • AARA Clinical Research Lone Star Arthritis and Rheumatology
      • Lubbock、Texas、アメリカ、79424
        • West Texas Clinical Research
      • Mesquite、Texas、アメリカ、75150
        • Southwest Rheumatology Research LLC
      • Red Oak、Texas、アメリカ、75154
        • Epic Medical Research
      • Tomball、Texas、アメリカ、77375
        • DM Clinical Research
    • Washington
      • Seattle、Washington、アメリカ、98104
        • Swedish Medical Center
      • Buenos Aires、アルゼンチン、C1199ABB
        • Hospital Italiano de Buenos Aires
      • Buenos Aires、アルゼンチン、C1417
        • Centro Privado de Medicina Familiar
      • Buenos Aires、アルゼンチン、1428
        • Cosultorios Reumatologógicos Pampa
      • La Plata、アルゼンチン、B1900
        • Hospital Italiano La Plata
      • San Fernando、アルゼンチン、B1646
        • MR Medicina Reumatologica
      • San Miguel de Tucumán、アルゼンチン、T4000AXL
        • Centro Medico Privado de Reumatologia
      • Barnet、イギリス、EN5 3DJ
        • Royal Free London NHS Foundation Trust
      • Bradford、イギリス、BD5 0NA
        • St. Lukes Hospital
      • Coventry、イギリス、CV2 2DX
        • University Hospital Coventry & Warwickshire NHS Trust
      • Leeds、イギリス、LS7 4SA
        • Chapel Allerton Hospital
      • Manchester、イギリス、M13 9WL
        • Central Manchester University Hospitals NHS Foundation Trust
      • Newcastle、イギリス、NE29 8NH
        • North Tyneside General Hospital
      • Stoke-on-Trent、イギリス、ST6 7AG
        • Haywood Hospital
      • Haifa、イスラエル、31048
        • Bnai Zion Medical Center
      • Haifa、イスラエル、34362
        • Carmel Medical Center
      • Holon、イスラエル、5822012
        • Wolfson Medical Center
      • Kfar Saba、イスラエル、4428164
        • Meir Medical Center
      • Ramat Gan、イスラエル、5265601
        • Sheba Medical Center
      • Ancona、イタリア、60126
        • A.O. Universitaria Ospedali Riuniti di Ancona
      • Monserrato、イタリア、09124
        • Azienda Ospedaliero-Universitaria di Cagliari
      • Reggio Emilia、イタリア、42123
        • Arcispedale Santa Maria Nuova - IRCCS
      • Roma、イタリア、00133
        • Policlinico Tor Vergata
      • Rozzano (MI)、イタリア、20089
        • Humanitas Hospital
      • Verona、イタリア、37126
        • Azienda Ospedaliera Universitaria Integrata Verona
      • Cherkasy、ウクライナ、18009
        • Communal Noncommercial Enterprise Cherkasy Regional Hospital of Cherkasy Regional Council
      • Kharkiv、ウクライナ、61204
        • Municipal non-commercial enterprise of Kharkiv Regional Council Regional Clinical Hospital
      • Khmelnytsky、ウクライナ、29000
        • Khmelnitckiy regional hospital
      • Kryvyi Rih、ウクライナ、50056
        • City Clinical Hospital No. 2
      • Kyiv、ウクライナ、03049
        • Kyiv Railway Clinical Hospital #2 Of Branch 'Health Center' Of The Company 'Ukrainian Railway'
      • Kyiv、ウクライナ、03680
        • SI National Scientific Center Institute of Cardiology of M.D. Strazhesko of NAMS of Ukraine
      • Kyiv、ウクライナ、02081
        • Medical Center of 'Institute of Rheumatology', LLC
      • Lutsk、ウクライナ、43005
        • Volyn Regional Clinical Hospital
      • Odesa、ウクライナ、65025
        • Municipal Non-profit Enterprise 'Odesa Regional Clinical Hospital' Odesa Regional Council
      • Poltava、ウクライナ、36011
        • ME Poltava Regional Clinical Hospital named after M.V. Sklifosovsky of Poltava Regional Consuil
      • Ternopil、ウクライナ、46002
        • Municipal institution of Tepnopil Regional Council 'Ternopil University Hospital'
      • Vinnytsia、ウクライナ、21009
        • Health Clinic Limited Liability Company
      • Zaporizhzhya、ウクライナ、69600
        • Medical Center LLC 'Modern Clinic'
      • Camberwell、オーストラリア、3124
        • Emeritus Research
      • Hobart、オーストラリア、7000
        • Southern Clinical Research
      • Liverpool、オーストラリア、2170
        • Liverpool Hospital
      • Maroochydore、オーストラリア、4558
        • Rheumatology Research Unit
      • Melbourne、オーストラリア、3128
        • Eastern Health - Box Hill Hospital
      • Melbourne、オーストラリア、3053
        • Skin Health Institute Inc.
    • British Columbia
      • Vancouver、British Columbia、カナダ、V5Z 4E8
        • Skin Care Centre
    • Newfoundland and Labrador
      • St. John's、Newfoundland and Labrador、カナダ、A1C 5B8
        • Eastern Regional Health Authority St Clares Mercy Hospital
    • Ontario
      • Toronto、Ontario、カナダ、M5T 2S8
        • Toronto Western Hospital
    • Quebec
      • Québec、Quebec、カナダ、G1V 3M7
        • G R M O Groupe de recherche en maladies osseuses Inc
      • Batumi、グルジア、6010
        • Ltd Health Center
      • Kutaisi、グルジア、4600
        • LTD Clinic LJ
      • Tbilisi、グルジア、0112
        • LTD Helsicore
      • Tbilisi、グルジア、0102
        • Aleksandre Aladashvili Clinic LLC
      • Tbilisi、グルジア、0141
        • TSMU The First University Clinic
      • Tbilisi、グルジア、0179
        • Clinic on Mtskheta Street
      • Tbilisi、グルジア、0186
        • Consilium Medulla-multiprofile clinic Ltd
      • Tbilisi、グルジア、0160
        • LTD MediClub Georgia
      • Tbilisi、グルジア、0180
        • LTD The First Medical Center
      • Tbilisi、グルジア、0160
        • LTD 'Aversi Clinic'
      • Tbilisi、グルジア、0102
        • Ltd American Hospital Network
      • Tbilisi、グルジア、0159
        • JSC K Eristavi National Center of experimental and Clinical surgery
      • Tbilisi、グルジア、0159
        • Tbilisi Heart and Vascular Clinic Ltd
      • Tbilisi、グルジア、0114
        • Ltd New Hospitals
      • Tnilisi、グルジア、0159
        • JSC Evex Hospitals
      • Solna、スウェーデン、171 76
        • Karolinska Universitetssjukhuset
      • Uppsala、スウェーデン、753 09
        • Akademiska Sjukhuset
      • A Coruña、スペイン、15006
        • Hosp Univ A Coruna
      • Barakaldo、スペイン、48902
        • Hosp. Univ. de Cruces
      • Barcelona、スペイン、08036
        • Hosp Clinic de Barcelona
      • Bilbao、スペイン、48013
        • Hosp. Univ. de Basurto
      • Córdoba、スペイン、14004
        • Hosp Reina Sofia
      • Madrid、スペイン、28040
        • Hosp. Clinico San Carlos
      • Málaga、スペイン、29009
        • Hosp Regional Univ de Malaga
      • Sabadell、スペイン、8208
        • Corporacio Sanitari Parc Tauli
      • Santiago de Compostela、スペイン、15702
        • Clinica Gaias
      • Seville、スペイン、41009
        • Hosp. Virgen Macarena
      • Seville、スペイン、41013
        • Hosp. Quiron Sagrado Corazon
      • Valencia、スペイン、46026
        • Hosp. Univ. I Politecni La Fe
      • Martin、スロバキア、036 01
        • Reumatologicka Ambulancia 1
      • Nové Mesto nad Váhom、スロバキア、91501
        • Reumatologicka ambulancia
      • Piešťany、スロバキア、921 01
        • Reumatologická ambulancia Thermium s.r.o.
      • Poprad、スロバキア、05801
        • REUMAMED POPRAD, s.r.o.
      • Rimavská Sobota、スロバキア
        • Reumex s.r.o
      • Bangkok、タイ、10400
        • Phramongkutklao Hospital and Medical College
      • Bangkok、タイ、10400
        • Ramathibodi Hospital Mahidol University
      • Chiang Mai、タイ、50200
        • Chiang Mai University
      • Brno、チェコ、61141
        • Revmaclinic
      • Brno、チェコ、63800
        • Revmatologie s r o
      • Brno-Židenice、チェコ、615 00
        • Revmacentrum MUDr Mostera s r o
      • Hlučín、チェコ、748 01
        • L K N Arthrocentrum
      • Karvina Frystat、チェコ、73301
        • Revimex Pro s r o
      • Ostrava、チェコ、70800
        • MUDr Rosypalova s r o
      • Pardubice、チェコ、53002
        • Arthrohelp S.R.O.
      • Prague、チェコ、128 00
        • Revmatologicky ustav
      • Uherské Hradiště、チェコ、68601
        • Medical Plus S R O
      • Frederiksberg、デンマーク、2000
        • Frederiksberg Hospital
      • Glostrup Municipality、デンマーク、2600
        • Rigshospitalet Glostrup
      • Køge、デンマーク、4600
        • Køge Sygehus Region Sjaelland
      • Vejle、デンマーク、7100
        • Vejle Sygehus
      • Adana、トルコ(Türkiye)、01370
        • Adana City Hospital
      • Ankara、トルコ(Türkiye)、06800
        • Ankara Bilkent City Hospital
      • Ankara、トルコ(Türkiye)、6100
        • Hacettepe University Medical Faculty
      • Ankara、トルコ(Türkiye)、06010
        • Gulhane Training and Research Hospital
      • Antalya、トルコ(Türkiye)、7059
        • Akdeniz University Medical Faculty
      • Bursa、トルコ(Türkiye)、16059
        • Uludag University Medical Faculty
      • Istanbul、トルコ(Türkiye)、34098
        • Istanbul University Cerrahpasa Medical Faculty
      • Istanbul、トルコ(Türkiye)、34899
        • Marmara University Medical Faculty
      • Konya、トルコ(Türkiye)、42080
        • Necmettin Erbakan University Meram Medical Faculty
      • Berlin、ドイツ、10789
        • ISA - Interdisciplinary Study Association GmbH
      • Hamburg、ドイツ、20095
        • Hamburger Rheuma Forschungszentrum II
      • Herne、ドイツ、44649
        • Rheumazentrum Ruhrgebiet
      • Ratingen、ドイツ、40878
        • Rheumazentrum Ratingen
      • Budapest、ハンガリー、1036
        • Obudai Egeszsegugyi Centrum Kft
      • Budapest、ハンガリー、1023
        • Betegapolo Irgalmas Rend Budai Irgalmasrendi Korhaz
      • Budapest、ハンガリー、H-1036
        • Qualiclinic Kft
      • Gyula、ハンガリー、5700
        • Bekes Varmegyei Kozponti Korhaz Pandy Kalman Tagkorhaz
      • Hódmezővásárhely、ハンガリー、6800
        • Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
      • Kistarcsa、ハンガリー、2143
        • Kistarcsai Flor Ferenc Korhaz
      • Székesfehérvár、ハンガリー、8000
        • Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
      • Veszprém、ハンガリー、8200
        • Vital Medical Center Orvosi es Fogaszati Kozpont
      • Cebu City、フィリピン、6000
        • Cebu Doctors' University Hospital
      • Davao City、フィリピン、8000
        • Davao Doctors Hospital
      • Lipa、フィリピン、4217
        • Lipa Medix Medical Hospital
      • Manila、フィリピン、1000
        • Philippine General Hospital
      • Manila、フィリピン、1000
        • ManilaMed Medical Center Manila
      • Quezon City、フィリピン、1112
        • St. Luke's Medical Center
      • San Fernando City、フィリピン、2500
        • Ilocos Training and Regional Medical Center
      • Pleven、ブルガリア、5804
        • UMHAT 'Dr. Georgi Stranski', EAD
      • Pleven、ブルガリア、5803
        • Exacta Medica
      • Plovdiv、ブルガリア、4001
        • UMHAT Kaspela
      • Plovdiv、ブルガリア、4001
        • Medical Center Unimed Plovdiv
      • Plovdiv、ブルガリア、4002
        • Medical Center Artmed
      • Sofia、ブルガリア、1606
        • Military Medical Academy
      • Sofia、ブルガリア、1680
        • DCC Convex EOOD
      • Sofia、ブルガリア、1794
        • Medical Centre Synexus
      • Sofia、ブルガリア、1336
        • MHAT 'Lyulin' EAD
      • Sofia、ブルガリア、1612
        • UMHAT St. Ivan Rilski
      • Sofia、ブルガリア、1750
        • ASIMP Rheumatology Centre St Irina EOOD
      • Sofia、ブルガリア、1336
        • University Multiprofile Hospital Sofiamed Sofia
      • Targovishte、ブルガリア、7700
        • DDC Sv. Ivan Rilski OOD
      • Braga、ポルトガル、4710-243
        • Uls Braga - Hosp. Braga
      • Guarda、ポルトガル、6300-749
        • Ulsg - Hosp. Sousa Martins
      • Lisbon、ポルトガル、1350-352
        • Hosp. Cuf Tejo
      • Lisbon、ポルトガル、1649-035
        • Uls Santa Maria - Hosp. Santa Maria
      • Lisbon、ポルトガル、1050 034
        • Ipr Inst Port de Reumatologia
      • Lisbon、ポルトガル、1349-019
        • Uls Lisboa Ocidental - Hosp. Egas Moniz
      • Ponte de Lima、ポルトガル、4990-041
        • Ulsam - Hosp. Conde de Bertiandos
      • Porto、ポルトガル、4200 319
        • Uls Sao Joao - Hosp. Sao Joao
      • Bialystok、ポーランド、15 879
        • ClinicMed Daniluk Nowak Spolka Komandytowa
      • Bydgoszcz、ポーランド、85 168
        • Szpital Uniwersytecki nr 2 im dr Jana Biziela
      • Bytom、ポーランド、41 902
        • Nzoz Bif Med
      • Elblag、ポーランド、82-300
        • Centrum Kliniczno Badawcze
      • Elblag、ポーランド、82-300
        • Ambulatorium sp. z o.o.
      • Krakow、ポーランド、30-002
        • Malopolskie Badania Kliniczne Sp z o o
      • Krakow、ポーランド、31-513
        • Centrum Medyczne Promed
      • Lodz、ポーランド、90-338
        • Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna
      • Lodz、ポーランド、90-265
        • Dermed Centrum Medyczne Sp z o o
      • Lodz、ポーランド、91 363
        • Centrum Medyczne AMED oddzial w Lodzi
      • Lublin、ポーランド、20 607
        • Reumed Zespol Poradni Specjalistycznych Filia nr 1
      • Lublin、ポーランド、20-412
        • Pro Life Medica Sp. z o.o.
      • Lublin、ポーランド、20 831
        • Velocity Lublin
      • Nadarzyn、ポーランド、05-830
        • NZOZ Lecznica MAK MED S C
      • Nowa Sól、ポーランド、67-100
        • Twoja Przychodnia - Centrum Medyczne Nowa Sol
      • Poznan、ポーランド、60 324
        • Twoja Przychodnia PCM
      • Poznan、ポーランド、60-446
        • Reumedika s c Wieslawa Porawska Lukasz Porawski
      • Torun、ポーランド、87-100
        • MICS Centrum Medyczne Torun
      • Warsaw、ポーランド、02-793
        • ETG Warszawa
      • Warsaw、ポーランド、00-874
        • MICS Centrum Medyczne Warszawa
      • Warsaw、ポーランド、02 637
        • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
      • Warsaw、ポーランド、02-665
        • Centrum Medyczne Reuma Park
      • Warsaw、ポーランド、02 118
        • Rheuma Medicus Sp z o o
      • Warsaw、ポーランド、03 291
        • Centrum Medyczne AMED Targowek
      • Wroclaw、ポーランド、51 685
        • WroMedica I Bielicka A Strzalkowska s c
      • Świdnik、ポーランド、21 040
        • Lubelskie Centrum Diagnostyczne
      • Batu Caves、マレーシア、68100
        • Hospital Selayang
      • George Town、マレーシア、10990
        • Hospital Pulau Pinang
      • Johor Bahru、マレーシア、81100
        • Hospital Sultan Ismail
      • Kuala Lumpur、マレーシア、59100
        • University Malaya Medical Centre
      • Seremban、マレーシア、70300
        • Hospital Tuanku Jaafar
      • Barnaul、ロシア、656038
        • Altay Medical State University
      • Chelyabinsk、ロシア、454076
        • Chelyabinck Regional Clinical Hospital
      • Chelyabinsk、ロシア、454092
        • Chelyabinsk Regional Clinical Dermatovenerological Dispensary
      • Izhevsk、ロシア、426009
        • Regional Clinical Diagnostic Center of Udmurtia Region
      • Kemerovo、ロシア、650070
        • LLL Medical Center Revma-Med
      • Korolyov、ロシア、141060
        • LLC Family Outpatient Clinic # 4
      • Krasnoyarsk、ロシア、660123
        • Regional SBI of PH Krasnoyarsk Regional Clinical hospital #20 named after I.S. Berzon
      • Moscow、ロシア、115419
        • Clinical-Diagnostic Center Euromedservice, JSC
      • Moscow、ロシア、115522
        • FGBU Research Institute of Rheumatology named V.A.Nasonova
      • Moscow、ロシア、129110
        • GBUZ of Moscow Region 'Moscow Region SRI n.a. Vladimirskyi'
      • Omsk、ロシア、644024
        • Llc Ultramed
      • Orenburg、ロシア、460000
        • GBOU VPO Orenburg State Medical University
      • Perm、ロシア、614990
        • GBUZ Perm Regional Clinical Hospital
      • Petrozavodsk、ロシア、185019
        • Republican Hospital n.a.V.A.Baranov
      • Rostov-on-Don、ロシア、344007
        • Rostov Regional Clinical Dermatovenerological Dispensary
      • Saint Petersburg、ロシア、190068
        • St. Petersburg GBUZ Clinical Reumatological Hospital 25
      • Saint Petersburg、ロシア、194156
        • X7 Clinical Research Company Limited
      • Tolyatti、ロシア、445846
        • GBUZ of Samara Region 'Tolyatti City Clinical Hospital 5'
      • Ufa、ロシア、450005
        • Republican Clinical Hospital - G.G. Kuvatov
      • Yaroslavl、ロシア、150007
        • Clinical Hospital #3
      • Yekaterinburg、ロシア、620102
        • Sverdlovsk Regional Clinical Hospital N. 1
      • Hsinchu、台湾、30059
        • National Taiwan University Hospital
      • Tainan、台湾、704
        • National Cheng Kung University Hospital
      • Taoyuan、台湾、33305
        • Linkou Chang Gung Memorial Hospital
      • Hong Kong、香港
        • Prince Of Wales Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Have a diagnosis of psoriatic arthritis (PsA) for at least 6 months prior to the first administration of study intervention and meet classification criteria for psoriatic arthritis (CASPAR) criteria at screening
  • Have active PsA as defined by: a) at least 3 swollen joints and at least 3 tender joints at screening and at baseline and b) C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligram/deciliter (mg/dL) at screening from the central laboratory, and despite previous non-biologic disease modifying antirheumatic drug (DMARD), apremilast, and/or nonsteroidal anti-inflammatory drug (NSAID) therapy
  • Have magnetic resonance imaging (MRI)-confirmed PsA axial disease (positive MRI spine and/or sacroiliac [SI] joints, shown by a Spondyloarthritis Research Consortium of Canada [SPARCC] score of >= 3 in either the spine or the sacroiliac joints)
  • Have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4, and have a spinal pain score (on a visual analog scale [VAS]) of at least 4
  • Have active plaque psoriasis, with at least 1 psoriatic plaque of >= 2 centimeter (cm) diameter and/or nail changes consistent with psoriasis, or documented history of plaque psoriasis

Exclusion Criteria:

  • Has known allergies, hypersensitivity, or intolerance to guselkumab or its excipients
  • Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to rheumatoid arthritis (RA), ankylosing spondylitis (AS)/non-radiographic-axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, or Lyme disease
  • Has previously received any biologic treatment
  • Has ever received a Janus kinase (JAK) inhibitor including but not limited to tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other investigational JAK inhibitor
  • Has received any systemic immunosuppressants (example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Group 1: Guselkumab and Placebo

Participants will receive guselkumab and matching placebo subcutaneously (SC) to maintain the blind.

Guselkumab will be administered as subcutaneous injection.

他の名前:
  • トレムフィア

Matching placebo will be administered as subcutaneous injection.

実験的:Group 2: Guselkumab

Participants will receive guselkumab SC.

Guselkumab will be administered as subcutaneous injection.

他の名前:
  • トレムフィア
実験的:Group 3: Placebo followed by Guselkumab

Participants will receive matching placebo and will cross over to receive guselkumab SC.

Guselkumab will be administered as subcutaneous injection.

他の名前:
  • トレムフィア

Matching placebo will be administered as subcutaneous injection.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Week 24
時間枠:Baseline and Week 24

BASDAI is a self-assessment tool that consists of 6 questions relating to 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. First 5 items were scored on a 10 centimeter (cm) visual analog scale (VAS) ranging from 0 equals to (=) none to 10=very severe. Quantitative morning stiffness was scored on a 10 cm VAS ranging from 0=0 hours to 10=2 or more hours. 2 scores for qualitative and quantitative morning stiffness were averaged, and total BASDAI score was average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity.

Baseline and Week 24

二次結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein (ASDAS-CRP) at Week 24
時間枠:Baseline and Week 24

The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the C-reactive protein (CRP) value. Selected cut-offs for improvement scores are: a change greater than or equal to (>=) 1.1 units for "clinically important improvement" and a change >= 2.0 units for "major improvement.

Baseline and Week 24
Change from Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Week 24
時間枠:Baseline and Week 24

DAPSA assessed the joint domain of psoriatic arthritis (PsA) and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (milligram/deciliter [mg/dL], value less than [<] lower limit of quantification [LLOQ] is considered equal to half of the value of LLOQ for numerical calculations), participant assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and participant's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

Baseline and Week 24
Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 24
時間枠:Baseline and Week 24

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

Baseline and Week 24
Percentage of Participants with Investigator's Global Assessment (IGA) 0/1 Response at Week 24 among Participants with >= 3% Body Surface Area (BSA) Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
時間枠:Week 24

Percentage of participants with IGA 0/1 response at week 24 among the participants with >= 3 percent (%) BSA psoriatic involvement and an IGA score of >= 2 (mild) at baseline will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given timepoint. Overall lesions are graded for induration, erythema, and scaling using 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate) and 4 (severe) scale. The IGA score of psoriasis is based upon the average of induration, erythema and scaling scores. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 24
Change from Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Score for Magnetic Resonance Imaging (MRI) Sacroiliac (SI) Joints at Week 24
時間枠:Baseline and Week 24

Change from baseline in SPARCC score for MRI SI joints at week 24 among the participants with a positive MRI of the sacroiliac joints at baseline will be reported. SPARCC method focuses on the cartilaginous portion of the SI joint, and scores presence (score of 1) versus absence (score of 0) of bone marrow edema in each SI joint quadrant.

Baseline and Week 24
Percentage of Participants who Achieve a >= 50 % Improvement from Baseline in BASDAI Score at Week 24
時間枠:Baseline and Week 24

Percentage of participants who achieve a >= 50 % improvement from baseline in BASDAI score at week 24 will be reported.

Baseline and Week 24
Percentage of Participants who Achieve ASDAS Clinically Important Improvement at Week 24
時間枠:Week 24

Percentage of participants who achieve ASDAS clinically important improvement at week 24 will be reported.

Week 24
Percentage of Participants who Achieve Ankylosing Spondylitis Activity Score (ASAS) 40 Response at Week 24
時間枠:Week 24

Percentage of participants who achieve ASAS 40 response at Week 24 will be reported. ASAS 40 defined as improvement from baseline of >= 40% and with an absolute improvement from baseline of at least 2 on 0 to 10 cm scale in at least 3 of following 4 domains: Participant's global assessment (0 to 10 cm; 0=very well, 10=very poor), total back pain (0 to 10 cm; 0=no pain,10=most severe pain), BASFI (self-assessment represented as mean (0 to 10 cm; 0=easy to 10=impossible) of 10 questions, 8 of which relate to participant's functional anatomy and 2 relate to participant's ability to cope with everyday life), Inflammation (0 to 10 cm; 0=none, 10=very severe); no worsening at all from baseline in remaining domain.

Week 24
Percentage of Participants who Achieve ASDAS Major Improvement at Week 24
時間枠:Week 24

Percentage of participants who achieve ASDAS major improvement at Week 24 will be reported.

Week 24
Change from Baseline in SPARCC Score for MRI Spine at Week 24
時間枠:Baseline and Week 24

Change from baseline in SPARCC score for MRI spine at week 24 among the participants with a positive MRI of the spine at baseline will be reported. The SPARCC scoring system for the spine scores the 6 discovertebral units considered by the reader as the most abnormal, and then separately assesses each quadrant of 3 adjacent sagittal slices, with additional points for "depth" and high "intensity" of the lesion.

Baseline and Week 24
Number of Participants with Adverse Events (AEs)
時間枠:Up to 60 weeks

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 60 weeks
Number of Participants with Serious Adverse Events (SAEs)
時間枠:Up to 60 weeks

A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.

Up to 60 weeks
Number of Participants with Reasonably Related AEs
時間枠:Up to 60 weeks

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 60 weeks
Number of Participants with AEs Leading to Discontinuation of Study Intervention
時間枠:Up to 60 weeks

Number of participants with AEs leading to discontinuation of study intervention will be reported.

Up to 60 weeks
Number of Participants with Infections
時間枠:Up to 60 weeks

Number of participants with infections will be reported.

Up to 60 weeks
Number of participants with Injection-Site Reactions
時間枠:Up to 60 weeks

Number of participants with injection-site reactions will be reported. A study intervention injection-site reaction is any adverse reaction at a subcutaneous study intervention injection-site.

Up to 60 weeks
Number of Participants with Laboratory Abnormalities (Chemistry, Hematology) by Maximum Toxicity (Common Terminology Criteria for Adverse Events [CTCAE 5.0]) Grades
時間枠:Up to 60 weeks

Number of participants with laboratory abnormalities (chemistry, hematology) by maximum toxicity (CTCAE 5.0) grades will be reported. Grade refers to the severity of the AE as follows: Grade 1- Mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2- Moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental Activities of Daily Living (ADL); Grade 3- Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care ADL; Grade 4- Life-threatening consequences, urgent intervention indicated; Grade 5- Death related to AE.

Up to 60 weeks
Serum Guselkumab Concentration Over Time
時間枠:Up to 60 weeks

Serum guselkumab concentration over time will be reported.

Up to 60 weeks
Number of Participants with Antibodies to Guselkumab
時間枠:Up to 60 weeks

Number of participants with antibodies to guselkumab will be reported.

Up to 60 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年8月30日

一次修了 (推定)

2027年4月1日

研究の完了 (推定)

2027年4月13日

試験登録日

最初に提出

2021年6月11日

QC基準を満たした最初の提出物

2021年6月11日

最初の投稿 (実際)

2021年6月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • CR109043
  • 2021-000465-32 (EudraCT番号)
  • CNTO1959PSA4002 (その他の識別子:Janssen Research & Development, LLC)
  • 2023-504716-15-00 (レジストリ識別子:EUCT number)
  • 2023 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する